Biliary tract carcinoma.
Concurrent febrile illness, active urinary tract infection, active tuberculosis, a history of hypotension or anaphylactic reactions
Has an active infection requiring systemic therapy within 3 days of registration (NOTE: except for uncomplicated urinary tract infection [UTI])
Intraoperative frozen section suggesting hepatobiliary, pancreatic, adrenal, or urinary tract cancer
Patients with active infection requiring antibiotics are not eligible (with the exception of uncomplicated UTI and uncomplicated respiratory tract infections)
Patients should be free of active infection requiring antibiotics (with the exception of uncomplicated urinary tract infection [UTI])
Patients who have an active infection requiring systemic therapy are not eligible, except for uncomplicated urinary tract infections
The patient has any ongoing or active infection, including active tuberculosis; Note: a urinary tract infection controlled with oral antibiotics initiated at least 7 days prior to study entry is acceptable
Acute urinary tract infection.
Lower urinary tract symptoms defined by International Prostate symptom score (IPSS) > 20
Carcinoma in situ (CIS) in the past in the urinary tract.
Known untreated or uncontrolled acute infection, including urinary tract infection, within 7 days of study entry
Patients should be free of active infection requiring antibiotics (with the exception of uncomplicated urinary tract infection [UTI])
Active infection requiring antibiotics (with the exception of uncomplicated urinary tract infection)
Have known urinary outflow obstruction, or inflammation of the urinary bladder (cystitis).
No characteristics suggesting a potential higher risk of infection with intraprostatic injections:\r\n* Recurrent urinary tract infections or history of prostatitis within 3 months prior to enrollment into the study\r\n* Urine analysis positive for nitrites and leucocyte esterase; such patients could be considered for the study after treatment and resolution of the infection\r\n* Active proctitis\r\n* History of prostatic abscess\r\n* Taking immunosuppressive medication including systemic corticosteroids\r\n* Active hematologic malignancy
CHEMOTHERAPY/CELL INFUSION ELIGIBILITY: Urinalysis within 14 days demonstrating that no urinary tract infection is present
Urinary tract obstruction or marked hydronephrosis
Patients should be free of active infection requiring antibiotics (with the exception of uncomplicated urinary tract infection [UTI])
PHASE I: Patients should be free of active infection requiring antibiotic therapy (except for uncomplicated urinary tract infections)
PHASE II: Patients should be free of active infection requiring antibiotic therapy (except for uncomplicated urinary tract infections)
Current severe urinary incontinence, hydronephrosis, severe voiding dysfunction, any level of urinary obstruction requiring indwelling/condom catheters
All types of urinary diversions
Has an active infection requiring systemic therapy with the exception of an uncomplicated urinary tract infection
Active urinary tract infection
Urinary tract or rectal fistula
Patients should be free of active infection requiring antibiotics (with the exception of uncomplicated urinary tract infection [UTI])
Urinalysis within 14 days demonstrating no evidence of a urinary tract infection
Symptomatic urinary tract infection or bacterial cystitis (once satisfactorily treated, patients can enter the study)
Known urinary tract obstruction
History of recurrent severe urinary tract infections (UTIs) per investigator judgment. Subjects with a current UTI requiring antibiotic treatment may defer the initiation of Vicinium treatment on Day 1 until resolution of the UTI (even if this extends the screening period requirements to start of Vicinium treatment).
Acute unresolved Urinary Tract Infection (UTI)
Patients should be free of active infection requiring antibiotics (with the exception of an uncomplicated urinary tract infection [UTI])
Patients must have high grade upper tract urothelial carcinoma proven by one of the following:\r\n* Biopsy;\r\n* Urinary cytology with a 3-dimensional upper urinary tract mass on cross-sectional imaging; or\r\n* Urinary cytology and a mass visualized during upper urinary tract endoscopy
Urinary tract infection, including particularly bladder infection, must be resolved prior to being placed on study
Uncontrolled infection, fever > 100 degrees F; or antibiotic therapy < 72 hours prior to registration; or urinary tract infection < 72 hours prior to registration
active urinary tract infection;
urinary tract or rectal fistula;
Recent infection requiring a course of systemic anti-infectives that was completed =< 14 days prior to enrollment (exception can be made at the judgment of the PI for oral treatment of an uncomplicated urinary tract infection [UTI])
Patients must be free of active infections requiring antibiotics, with the exception of uncomplicated urinary tract infections (UTIs)
Prior or concomitant urothelial tumors of the upper urinary tract or urethra
Untreated urinary-tract infection
Upper urinary tract disease (eg, vesicoureteral reflux or urinary-tract stones) that would make multiple transurethral procedures a risk
Concurrent febrile illness, urinary tract infection, or gross hematuria
Patients should be free of active infection requiring antibiotics (with the exception of uncomplicated urinary tract infection [UTI])
No active infection requiring antibiotics (with the exception of uncomplicated urinary tract infection)
Active urinary tract infection
Clinically important genital/urinary tract dysfunction
Presence of an acute infection requiring antibiotics within 4 weeks of study entry or a chronic infection including but not limited to: urinary tract infection, HIV, viral hepatitis
Have an active urinary tract infection (UTI),
Have vaginal dryness, dyspareunia, or >= 3 urinary tract infections per year since starting AI therapy
Subjects with current or suspected urinary tract or bladder infection(s);
Patients with active urinary tract infections
Patient has systemic infection or evidence of any surgical site infection (superficial or organ space), including active urinary tract infection
Patients who have upper tract TCC
Documented acute prostatitis or urinary tract infections
Urine culture positive for significant urinary tract infection (UTI)
Patient has systemic infection or evidence of any surgical site infection (superficial or organ space), including active urinary tract infection